Polpar Sa (PPAR3) 시세

TSLZ.......................SYTA..............................https://stockcharts.com/h-sc/ui?s=TSLZ&p=W&yr=1&mn=3&dy=0&id=p96837884856

With this float it should be .003 +

Their focus is the 10 year. It’s going……..

as planned.

And they say, don’t fight the fed.

DP,




From a post by ANT....."Jon Jon. 1st I do not have an attorney handling this I'm handling it myself. An attorney would have cost 30-40,000 already. I am familiar with the Faro's attorney a very large multi state firm where junior attorneys cost 4-500 and se

Yesterday and today, my attempts to access groen-tech.com result in Norton flagging the site as a potential trojan-horse. While that's not necessarily the case, it does indicate another change to the website—by whom and why? Just curious.

tslz................................................................................................p/m

To bad for the board of company that the stock is sooooo low 🤮

We will see my friend. His first month in office has really hurt the market. I hope you are right

No need for personal attacks. I states an opinion. If you disagree that’s okay.

Why don't these GRIFTERS use their OWN money and buy at the market.... they are NOT AFRAID of the helplessly hopeful pennylongs.

Less than four one way or another. 

INLF....................................................................................p/m

OKTA
Okta upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Rudy Kessinger upgraded Okta to Buy from Neutral with a price target of $125, up from $90. The company reported "very strong" Q4 results and meaningfully raised its fiscal 2026 guidance, the analyst tells inve

These scummy insiders have done NOTHING but TAKE...they must believe the helplessly hopeful pennylongs are harmless to them.

mmmm


https://www.bloomberg.com/news/articles/2025-03-03/citi-copy-paste-error-almost-sent-6-billion-to-wealth-account

OKTA
Okta price target raised to $100 from $94 at Canaccord
Canaccord raised the firm's price target on Okta to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported resoundingly positive Q4 results ahead of both the firm's and consensus expectations with

MCHP
Microchip cyclical bottom may be forming, says JPMorgan

listening to your favorite song... over, and over, and over https://www.youtube.com/watch?v=BfnjX88Va4Y

"One example: the current CEO of Cytodyn was CMO under Nader Pourhassan the Frauder, and was fine with all his actions."

That is a false statement. It is a matter of public record how Dr JL felt about Nader. Stop trying to make it look like he was complicit with Nader's actions. It lo

"Oral bioavailability" is one of the most important properties in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity.

Nixon's Restaurants have not gone belly up


https://investorshub.advfn.com/uicon/155361.png?cb=636360310707230000
______________________________________________________________________


Nixon Restaurant Group Inc
is operated in Colorado ,

$ESLA @ $1.05....Given $16 one year target last week by highly regarded bio/pharma ETF...Hit $1.80s 2 weeks ago and backed off..$ESLA a repeat of Immuno $IOVA & $SMMT monster moves
Link: 9/29/24
https://finance.yahoo.com/news/estrella-immunopharma-achieves-complete-response-160000432.h

Grifter siraj...eom